Provided by Tiger Trade Technology Pte. Ltd.

LUYE PHARMA

2.160
+0.0150.70%
Volume:88.27M
Turnover:194.02M
Market Cap:8.63B
PE:11.65
High:2.315
Open:2.210
Low:2.150
Close:2.145
52wk High:3.940
52wk Low:1.730
Shares:4.00B
HK Float Shares:4.00B
Volume Ratio:2.51
T/O Rate:2.21%
Dividend:- -
Dividend Rate:- -
EPS(LYR):0.185
ROE:4.14%
ROA:2.44%
PB:0.46
PE(LYR):11.65
PS:1.17

Loading ...

A Look At Luye Pharma Group (SEHK:2186) Valuation As LY03020 Enters Phase II For Schizophrenia

Simply Wall St.
·
Apr 15

LUYE PHARMA Shares Climb Nearly 3% in Morning Session as Self-Developed Drug LY03020 Enrolls First Patient in Chinese Phase II Trial

Stock News
·
Apr 14

UBS Increases Stake in LUYE PHARMA by 13.95 Million Shares at HK$2.85 Each

Stock News
·
Apr 13

LUYE PHARMA's Innovative Drug LY03020 Enrolls First Patient in Chinese Phase II Trial

Stock News
·
Apr 08

Luye Pharma enrolls first patient in China Phase II trial of LY03020 schizophrenia drug

Reuters
·
Apr 08

Luye Pharma Maintains Stable Share Base in March 2026; USD 180 Million Convertible Bonds Allow Up to 288.79 Million New Shares

Bulletin Express
·
Apr 08

Undiscovered Gems In Asia Including 3 Promising Small Cap Stocks

Simply Wall St.
·
Apr 06

Luye Pharma Group (SEHK:2186) Valuation After Earnings Growth And Surprise 2025 Dividend Decision

Simply Wall St.
·
Apr 04

Stock Track | LUYE PHARMA Stock Soars 5.17% in Intraday Trading After Reporting Strong 2025 Profit Growth

Stock Track
·
Apr 02

LUYE PHARMA Shares Surge Nearly 5% on Strong 2025 Profit Growth

Stock News
·
Apr 02

Luye Pharma Group Books 31% Profit Growth in 2025; Shares Up 3%

MT Newswires Live
·
Mar 31

BRIEF-Luye Pharma Group Posts FY Net Income Attributable RMB618.7 MLN

Reuters
·
Mar 31

Luye Pharma 2025 Net Profit Up 9.4% to RMB705.70 Million as Oncology and CNS Sales Accelerate

Bulletin Express
·
Mar 31

Luye Pharma Group FY Net Income Attributable RMB 618.7 Million

THOMSON REUTERS
·
Mar 31

Luye Pharma Group FY Revenue RMB 6,308.4 Million

THOMSON REUTERS
·
Mar 31

Boan Biotech FY25 profit drops 90.24% to RMB 7.1 million; revenue rises 8.1% to RMB 780 million

Reuters
·
Mar 30

LUYE PHARMA (02186) Sets 30 Mar 2026 Board Meeting to Approve FY 2025 Results and Consider Final Dividend

Bulletin Express
·
Mar 17

LUYE PHARMA (02186) Monthly Return Announcement for February 2026

Bulletin Express
·
Mar 05